Banook Group consolidates three subsidiaries under one unique name and brand

Banook Group, an international provider of cardiac safety, central imaging and endpoint adjudication services, today announces that its three subsidiaries will now be combined into one unique name and brand.

To accompany the rebrand, Banook Group has introduced a new logo and launched a new website (www.banookgroup.com).

The group’s subsidiaries: CardiaBase (Nancy, France), a cardiac core laboratory, Banook Central Imaging (Nancy, France), a global service organization providing medical image management for clinical research and Banook Inc. (Mystic, CT, USA), the US operational base, are now gathered under the Banook Group name. The three entities remain wholly owned subsidiaries.

Using a single name reinforces the group’s strategy in centralizing its activities, expanding its line of services and strengthening its global positioning.

The rebrand remains in line with the group’s strategy; as the Banook Group is now one of the few groups able to offer a complete range of services in these three areas: cardiac safety, central imaging and endpoint adjudication.

Banook Group’s mission is to help its clients conduct clinical trials of the highest quality in the least amount of time, to secure regulatory approval and ultimately bring new solutions to the market for the benefit of patients worldwide.

Since its establishment in 1999, the group has achieved tremendous growth, including a 20% increase in turnover last year and diversification in its business activities. This rebrand is an important milestone for the Banook Group. It will help with the implementation of its worldwide growth strategy.

“Banook Group highly values improving the life of millions of patients throughout the world,” said Dr. Pascal Voiriot, president of Banook Group. “Banook Group represents a simple and modern update to the visual identity of the company. It is indicative of our corporate culture and commitment to connecting science and people. We never forget that behind the numbers, metrics and data flows, there are patients.”

Banook Group’s key figures:

• More than 125 clients placed their trust in Banook Group, including global pharmaceutical groups, device manufacturers, biotech companies, academic institutes and Non Profit Organizations
• 50 full-time employees and 35 medical experts based in Europe and the US
• Analysis of data gathered from more than 60,000 patients and healthy volunteers
• Over 750 projects have been conducted since 1999, including 300 intense ECGs trials
• Over 1,000 hospitals and clinical sites already equipped with ECG recorders in more than 50 countries
• Over 1 million ECGs analyses performed since the beginning of activities
• Over 15,000 patient files adjudicated by our independent expert teams
• Certified to submit data to the FDA ECG Warehouse

Between 2014 and 2018, the CRO market is expected to grow at a 7.9% annual rate and reach the $32Bn mark in 2018 (source: ISR Report). The central and core laboratories market (including cardiac safety and imaging assessment) represents almost 10% of this market ($3Bn a year) and is vital to the successful development of new drugs.